In the univariate analyses, younger age, the use of mTOR inhibitors, polytherapy with two or more ASDs, recurrent seizures, all TSC manifestation categories, the total number of TSC manifestations, and the level of disability were associated with higher direct costs. This evidence concerns the gene MTOR and tuberous sclerosis.